SCHEMBL167447

SCHEMBL167447

CC(=O)c1c(F)cccc1F

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.64
CES1 P23141 4/20 0.64
THRB P10828 1/20 0.54
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 2/20 0.48
LMNA P02545 1/20 0.47
MEN1 O00255 1/20 0.45
BCHE P06276 1/20 0.44
GAA P10253 1/20 0.44
POLB P06746 1/20 0.43
HTT P42858 2/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
NOD2 Q9HC29 1/20 0.42
ALB P02768 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12160758 0.86 CES2 (0.54) CES2CES1THRBKMT2ATDP1
SCHEMBL467416 0.86 THRB (0.71) CES2CES1THRBKMT2ATDP1
SCHEMBL30116840 0.84 CES2 (0.52) CES2CES1THRBKMT2ATDP1
SCHEMBL14416609 0.84 CES2 (0.52) CES2CES1THRBKMT2ATDP1
SCHEMBL13040776 0.84 CES2 (0.52) CES2CES1THRBKMT2ATDP1
SCHEMBL14454258 0.84 CES2 (0.52) CES2CES1THRBKMT2ATDP1
SCHEMBL29443043 0.84 GAA (0.54) CES2CES1KMT2ALMNAMEN1
SCHEMBL716550 0.84 GAA (0.54) CES2CES1KMT2ALMNAMEN1
SCHEMBL4119544 0.84 CES2 (0.52) CES2CES1THRBKMT2ATDP1
SCHEMBL1957640 0.81 CA9 (0.57) CES2CES1THRBKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119926191-B Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-06-13 CN claimed
CN-119926191-A Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-05-06 CN claimed
CN-119859094-A Preparation method of 2, 6-dihydroxyacetophenone 湖南卢普药业有限公司 2025-04-22 CN claimed
CN-118459422-A Thiazole thiazolinone compound containing multiple halogen atoms and preparation method thereof 南京工业大学 2024-08-09 CN claimed
CN-118459420-A Thiazolinone compound containing multiple halogen atoms and preparation method thereof 南京工业大学 2024-08-09 CN claimed
CN-114950159-B Preparation method of aromatic polymer separation membrane based on super acid catalysis 南京工业大学 2023-06-06 CN claimed
CN-116041212-A Preparation and application of difluoro olefin ether and oxime ether derivatives 安徽农业大学 2023-05-02 CN claimed
CN-114950159-A Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation 南京工业大学 2022-08-30 CN claimed
CN-112608277-B Fluorine-containing quinoline ester compound and preparation method and application thereof 浙江工业大学 2022-08-05 CN claimed
CN-113135590-B Preparation method of perovskite nanorod 南京邮电大学 2022-04-01 CN claimed
CN-113233498-A Method for adjusting perovskite luminescence wavelength by fluoride 南京邮电大学 2021-08-10 CN claimed
CN-113135590-A Preparation method of perovskite nanorod 南京邮电大学 2021-07-20 CN claimed
CN-112608277-A Fluorine-containing quinoline ester compound and preparation method and application thereof 浙江工业大学 2021-04-06 CN claimed
US-9174906-B2 Process for producing optically active secondary alcohol KANTO KAGAKU KABUSHIKI KAISHA (JP) 2015-11-03 US claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
JP-4711621-B2 2011-06-29 JP claimed
US-20050256333-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2005-11-17 US claimed
EP-1461323-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2004-09-29 EP claimed
WO-2002100341-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2002-12-19 WO claimed
EP-0660832-B1 SEROTONIN RECEPTOR AGENTS MERRELL PHARMA INC (US) 1998-01-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256333-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B CES2 425/4885CES1 45/4885THRB 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.